LUXTURNA Proves Effectiveness of Single Gene Therapy To Cure Rare Cause of Blindness

Monday, January 15, 2018

Foundation Fighting Blindness' Dr. Stephen Rose comments on the announcement of the FDA approval of LUXTURNA™ gene therapy for inherited blindness due to mutations in the RPE65 gene in an interview with MedicalResearch.com. Read the full interview and Dr. Rose's insight on MedicalResearch.com here.